Prevention of cardiovascular events at patients with arterial hypertension at treatmentangiotensin-converting enzyme inhibitor.

Cite item

Full Text


Angiotensin-converting enzyme inhibitor is one of basic antihypertensive drugs for treatment of arterial hypertension at first stages of
the disease. The review summarizes the data on different ACE inhibitors.


  1. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: 1245-53.
  2. 2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87.
  3. Диагностика и лечение артериальной гипертензии. Рекомендации ВНОК. Кардиоваск. тер. и проф. 2008; 7 (Прил. 2): 31.
  4. Anderson TJ, Overhiser R, Haber H. A comparative study of four antihypertensive agents on endothelian function in patients with coronary artery disease. J Am Coll Cardiol 2000; 35: 60-6.
  5. Карпов Ю.А. Клинические последствия ингибирования тканевого ангиотензинпревращающего фермента: целесообразность при стабильной ишемической болезни сердца. Кардиология. 2002; 6: 86-91.
  6. Kannel WB. Left ventricular hypertrophy as a risk factor in arterial hypertension. Eur Heart J 1992; 13 (Suppl. D): 82-8.
  7. Диагностика и лечение стабильной стенокардии Российские рекомендации. Разработаны Комитетом экспертов ВНОК. М., 2004.
  8. The HOPE Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high-risk patients. N Engl J Med 2000; 342: 145-53.
  9. The EUROPA investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.
  10. Функциональное состояние почек и прогнозирование сердечно-сосудистого риска. Рекомендации ВНОК и Научного общества нефрологов России. Кардиоваск. тер. и проф. 2008; 6 (Прил. 3).
  11. Sleight P. The rennin-angiotensin system: a review of trials with angiotensin-converting enzyme inhibitors and angiotensin receptor blocking agents. Eur Heart J 2002; 4 (Suppl. A): A53-7.
  12. Andraws R, Brown DL. Effect of inhibition of the rennin-angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 2007; 99: 1006-12.
  13. 2007 ESC Guidelines on Diabetes, Pre-Diabetes and Cardiovascular Diseases. Eur Heart J 2007; 28: 88-36.
  14. Верткин А.Л., Скотников А.С. Исследование ингибиторов ангиотензинпревращающего фермента у пациентов, перенесших острый инфаркт миокарда. Кардиология. 2008; 7: 14-7.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies